CA2832530C - Hsp90 inhibitors - Google Patents
Hsp90 inhibitors Download PDFInfo
- Publication number
- CA2832530C CA2832530C CA2832530A CA2832530A CA2832530C CA 2832530 C CA2832530 C CA 2832530C CA 2832530 A CA2832530 A CA 2832530A CA 2832530 A CA2832530 A CA 2832530A CA 2832530 C CA2832530 C CA 2832530C
- Authority
- CA
- Canada
- Prior art keywords
- group
- substituted
- unsubstituted
- alkynyl
- straight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161472061P | 2011-04-05 | 2011-04-05 | |
| US61/472,061 | 2011-04-05 | ||
| PCT/US2012/032371 WO2012138894A1 (en) | 2011-04-05 | 2012-04-05 | Hsp90 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2832530A1 CA2832530A1 (en) | 2012-10-11 |
| CA2832530C true CA2832530C (en) | 2021-02-16 |
Family
ID=48166734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2832530A Active CA2832530C (en) | 2011-04-05 | 2012-04-05 | Hsp90 inhibitors |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9346808B2 (https=) |
| EP (1) | EP2694505B1 (https=) |
| JP (1) | JP6266506B2 (https=) |
| KR (1) | KR102010222B1 (https=) |
| CN (1) | CN103582642B (https=) |
| AU (1) | AU2012240077C1 (https=) |
| BR (1) | BR112013025634A2 (https=) |
| CA (1) | CA2832530C (https=) |
| EA (1) | EA201391334A1 (https=) |
| MX (1) | MX360390B (https=) |
| WO (1) | WO2012138894A1 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9403828B2 (en) | 2005-02-01 | 2016-08-02 | Sloan-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| US7834181B2 (en) | 2005-02-01 | 2010-11-16 | Slaon-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| WO2008005937A2 (en) | 2006-06-30 | 2008-01-10 | Sloan-Kettering Institute For Cancer Research | Treatment of neurodegenerative diseases through inhibiton of hsp90 |
| JP5941407B2 (ja) | 2009-10-07 | 2016-06-29 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | Ｈｓｐ９０阻害剤 |
| JP6266506B2 (ja) | 2011-04-05 | 2018-01-24 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | Ｈｓｐ９０阻害物質 |
| CN103596955B (zh) | 2011-04-05 | 2016-11-16 | 索隆-基特林癌症研究协会 | Hsp90抑制剂 |
| EA201490230A1 (ru) * | 2011-07-08 | 2014-06-30 | Слоан-Кеттеринг Инститьют Фор Кэнсер Рисерч | Применение меченых ингибиторов hsp90 |
| EP2972394A4 (en) | 2013-03-15 | 2016-11-02 | Sloan Kettering Inst Cancer | HSP90-DESIGNING AND THERAPY |
| SG11201601542SA (en) | 2013-08-16 | 2016-04-28 | Sloan Kettering Inst Cancer | Selective grp94 inhibitors and uses thereof |
| WO2015138039A1 (en) * | 2013-12-23 | 2015-09-17 | Memorial Sloan-Kettering Cancer Center | Methods and reagents for radiolabeling |
| MX387627B (es) | 2014-09-17 | 2025-03-18 | Memorial Sloan Kettering Cancer Center | Formación de imágenes de inflamación e infección dirigida a hsp90 y terapia |
| US10118890B2 (en) | 2014-10-10 | 2018-11-06 | The Research Foundation For The State University Of New York | Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration |
| US20180280397A1 (en) | 2015-10-05 | 2018-10-04 | Memorial Sloan Kettering Cancer Center | Rational combination therapy for the treatment of cancer |
| CN111683658A (zh) * | 2017-06-23 | 2020-09-18 | 萨缪斯治疗股份有限公司 | 用于创伤性脑损伤及其后遗症的多蛋白复合物抑制剂疗法 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2287387C (en) | 1997-05-14 | 2010-02-16 | Sloan-Kettering Institute For Cancer Research | Methods and compositions for destruction of selected proteins |
| JP2002541255A (ja) | 1999-04-09 | 2002-12-03 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | Ｈｅｒ族チロシンキナーゼの分解および／または阻害方法および組成物 |
| US7439359B2 (en) | 2000-11-02 | 2008-10-21 | Sloan-Kettering Institute For Cancer Research | Small molecule compositions for binding to hsp90 |
| EP1395257A1 (en) | 2001-06-12 | 2004-03-10 | Elan Pharmaceuticals, Inc. | Macrocycles useful in the treatment of alzheimer's disease |
| WO2003037860A2 (en) | 2001-10-30 | 2003-05-08 | Conforma Therapeutics Corporation | Purine analogs having hsp90-inhibiting activity |
| EP1450784A4 (en) | 2001-11-09 | 2005-02-09 | Conforma Therapeutics Corp | HSP90-INHIBITABLE ZEARALANOL COMPOUNDS AND METHOD FOR THEIR PREPARATION AND USE |
| CN1649866A (zh) | 2002-02-28 | 2005-08-03 | 阿斯特拉曾尼卡有限公司 | 3－环状基－5－(含氮5－元环)甲基－噁唑烷酮衍生物及其作为抗菌药物的用途 |
| EP1620564A4 (en) | 2003-04-18 | 2008-03-12 | Cytovia Inc | METHOD FOR TREATING DISEASES RESPONSING TO APOPTOSIS INDUCTION AND SCREENING TESTS |
| MXPA06002997A (es) | 2003-09-18 | 2007-02-08 | Conforma Therapeutics Corp | Novedosos compuestos heterociclicos como inhibidores- hsp90. |
| US9403828B2 (en) | 2005-02-01 | 2016-08-02 | Sloan-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| US7834181B2 (en) | 2005-02-01 | 2010-11-16 | Slaon-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| WO2007075572A2 (en) | 2005-12-22 | 2007-07-05 | Conforma Therapeutics Corporation | Orally active purine-based inhibitors of heat shock protein 90 |
| WO2007134298A2 (en) | 2006-05-12 | 2007-11-22 | Myriad Genetics, Inc. | Therapeutic compounds and their use in cancer |
| WO2008005937A2 (en) | 2006-06-30 | 2008-01-10 | Sloan-Kettering Institute For Cancer Research | Treatment of neurodegenerative diseases through inhibiton of hsp90 |
| WO2008033747A2 (en) | 2006-09-11 | 2008-03-20 | Curis, Inc. | Multi-functional small molecules as anti-proliferative agents |
| FR2906824B1 (fr) | 2006-10-09 | 2008-12-26 | Roger Mondelin Sas Soc Par Act | Dispositif support de butees pour la pose de plaques de platre de largeur variable avec des appareils de levage et de manutention desdites plaques |
| CL2007002994A1 (es) * | 2006-10-19 | 2008-02-08 | Wyeth Corp | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. |
| GB0622084D0 (en) * | 2006-11-06 | 2006-12-13 | Chroma Therapeutics Ltd | Inhibitors of HSP90 |
| KR101313804B1 (ko) | 2007-03-20 | 2013-10-01 | 쿠리스 인코퍼레이션 | Ｈｓｐ９０ 억제제로서의 융합된 아미노 피리딘 |
| WO2008115262A2 (en) * | 2007-03-20 | 2008-09-25 | Curis, Inc. | Hsp90 inhibitors containing a zinc binding moiety |
| WO2009007399A1 (en) * | 2007-07-12 | 2009-01-15 | Crystax Pharmaceuticals, S.L. | New compounds as hsp90 inhibitors |
| WO2009042646A1 (en) | 2007-09-24 | 2009-04-02 | Curis, Inc. | Anti-proliferative agents |
| NZ586129A (en) * | 2007-11-14 | 2012-06-29 | Myrexis Inc | Therapeutic compounds and their use in treating diseases and disorders |
| EP2387316A4 (en) | 2009-01-16 | 2012-06-13 | Curis Inc | CONDENSED AMINOPYRIDINE FOR THE TREATMENT OF BRAIN TUMORS |
| GB0905328D0 (en) * | 2009-03-27 | 2009-05-13 | Ge Healthcare Ltd | Indole derivatives |
| CN102781520B (zh) * | 2009-07-17 | 2016-06-08 | 帕夫泰克技术私人有限公司 | 呼吸器 |
| GB0914543D0 (en) * | 2009-08-20 | 2009-09-30 | Ge Healthcare Ltd | Radioiodination method |
| JP5941407B2 (ja) | 2009-10-07 | 2016-06-29 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | Ｈｓｐ９０阻害剤 |
| CN103596955B (zh) | 2011-04-05 | 2016-11-16 | 索隆-基特林癌症研究协会 | Hsp90抑制剂 |
| JP6266506B2 (ja) | 2011-04-05 | 2018-01-24 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | Ｈｓｐ９０阻害物質 |
| SG11201601542SA (en) | 2013-08-16 | 2016-04-28 | Sloan Kettering Inst Cancer | Selective grp94 inhibitors and uses thereof |
-
2012
- 2012-04-05 JP JP2014503994A patent/JP6266506B2/ja not_active Expired - Fee Related
- 2012-04-05 EA EA201391334A patent/EA201391334A1/ru unknown
- 2012-04-05 CN CN201280027256.0A patent/CN103582642B/zh not_active Expired - Fee Related
- 2012-04-05 EP EP12717520.6A patent/EP2694505B1/en active Active
- 2012-04-05 CA CA2832530A patent/CA2832530C/en active Active
- 2012-04-05 AU AU2012240077A patent/AU2012240077C1/en not_active Ceased
- 2012-04-05 KR KR1020137029259A patent/KR102010222B1/ko not_active Expired - Fee Related
- 2012-04-05 US US14/009,976 patent/US9346808B2/en active Active
- 2012-04-05 WO PCT/US2012/032371 patent/WO2012138894A1/en not_active Ceased
- 2012-04-05 MX MX2013011532A patent/MX360390B/es active IP Right Grant
- 2012-04-05 BR BR112013025634A patent/BR112013025634A2/pt not_active IP Right Cessation
-
2016
- 2016-05-20 US US15/160,293 patent/US9926321B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2832530A1 (en) | 2012-10-11 |
| MX360390B (es) | 2018-10-31 |
| NZ616758A (en) | 2016-01-29 |
| AU2012240077B2 (en) | 2017-04-20 |
| EP2694505A1 (en) | 2014-02-12 |
| US20140088121A1 (en) | 2014-03-27 |
| CN103582642B (zh) | 2021-05-11 |
| AU2012240077A1 (en) | 2013-10-31 |
| WO2012138894A1 (en) | 2012-10-11 |
| KR20140062429A (ko) | 2014-05-23 |
| CN103582642A (zh) | 2014-02-12 |
| JP6266506B2 (ja) | 2018-01-24 |
| EA201391334A1 (ru) | 2014-06-30 |
| AU2012240077C1 (en) | 2017-08-10 |
| US9346808B2 (en) | 2016-05-24 |
| WO2012138894A4 (en) | 2012-12-06 |
| BR112013025634A2 (pt) | 2016-07-19 |
| KR102010222B1 (ko) | 2019-08-13 |
| JP2014510148A (ja) | 2014-04-24 |
| EP2694505B1 (en) | 2022-04-27 |
| US9926321B2 (en) | 2018-03-27 |
| MX2013011532A (es) | 2014-08-22 |
| US20160264577A1 (en) | 2016-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2832530C (en) | Hsp90 inhibitors | |
| AU2019364336B2 (en) | TYK2 inhibitors and uses thereof | |
| CN110546151B (zh) | 凋亡诱导剂 | |
| CA2832099C (en) | Hsp90 inhibitors | |
| CA2730271A1 (en) | Pi3k isoform selective inhibitors | |
| WO2008049105A2 (en) | Sulfamoyl-containing derivatives and uses thereof | |
| CA3077267A1 (en) | Fused heteroaryl ring derivatives useful as a2a receptor inhibitor | |
| NZ616758B2 (en) | Hsp90 inhibitors | |
| HK1194376B (en) | Hsp90 inhibitors | |
| HK1194376A (en) | Hsp90 inhibitors | |
| AU2013204109B2 (en) | Purine derivatives useful as hsp90 inhibitors | |
| JP2017061540A (ja) | Ｈｓｐ９０阻害物質 | |
| HK1194375B (en) | Hsp90 inhibitors | |
| HK1194375A (en) | Hsp90 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20170403 |
|
| H11 | Ip right ceased following rejected request for revival |
Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED Effective date: 20241007 |